Key Takeaways
- President Trump issued an executive order Saturday instructing the FDA to accelerate approval processes for psychedelic-based mental health treatments
- AtaiBeckley stock surged 28% in premarket activity; Compass Pathways climbed 26%
- The directive utilizes Commissioner’s National Priority Vouchers to reduce review periods from 6–10 months to just 1–2 months for drugs with “breakthrough therapy” designation
- Ibogaine, currently a Schedule I controlled substance under investigation for opioid addiction treatment, receives special mention in the executive order
- Federal funding of $50 million has been earmarked for ibogaine research initiatives
On Saturday, President Trump issued an executive order commanding the FDA to expedite the review process for psychedelic-based medications. The order bears the title “Accelerating Medical Treatments for Serious Mental Illness.”
The presidential mandate encompasses therapies targeting conditions such as treatment-resistant depression, post-traumatic stress disorder, and substance abuse disorders.
FDA Commissioner Marty Makary indicated that regulatory decisions on certain drugs could materialize as early as this summer.
The directive significantly compresses standard review timelines from 6–10 months to 1–2 months for medications already designated with “breakthrough therapy” status. This acceleration is achieved through the issuance of Commissioner’s National Priority Vouchers.
Psychedelic pharmaceutical companies experienced dramatic premarket gains Monday morning. AtaiBeckley surged 28%, Compass Pathways advanced 26%, GH Research increased 19%, Definium Therapeutics climbed 15%, Cybin posted approximately 15% gains, and Enveric BioSciences added 7%.
With a market capitalization approaching $1.5 billion, AtaiBeckley ranks among the largest publicly traded entities in the psychedelic pharmaceutical sector.
Market Response to White House Psychedelic Initiative
The company’s primary candidate, BPL-003, is a nasal spray formulation designed for treatment-resistant depression. Phase 3 clinical trials are scheduled to commence later this quarter.
Compass Pathways, a British biotechnology firm, is advancing COMP360, a synthetic psilocybin treatment. The drug is currently undergoing late-stage clinical trials for treatment-resistant depression and has already secured Breakthrough Therapy designation from the FDA.
The executive order makes explicit reference to ibogaine, a psychedelic compound extracted from an African shrub. Currently, ibogaine holds Schedule I controlled substance classification in the United States, indicating it is deemed to lack accepted medical applications.
Researchers are investigating ibogaine as a potential therapy for opioid addiction. The order directs regulatory bodies to facilitate access through the Right to Try Act, legislation Trump signed into law in 2018.
Ibogaine has been associated with documented cardiovascular risks, which have raised concerns among regulatory officials.
Federal Investment and Industry Expert Commentary
President Trump announced that $50 million in government funding would be dedicated to federal ibogaine research programs.
Jefferies analyst Andrew Tsai characterized the order as an “official stamp of validation to the class,” emphasizing that governmental backing is now tangible.
RBC analyst Brian Abrahams stated the signing “is a substantial step towards diminishing regulatory risk” for psychedelic medications.
Health Secretary Robert F. Kennedy Jr. has openly advocated for ibogaine as an alternative therapeutic approach for depression and additional mental health disorders.
Legislators across party lines have announced intentions to advance legislation broadening access to psychedelic-based therapies.
FDA Commissioner Makary verified the agency stands ready to implement expedited procedures under the new presidential directive.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
